Pacira Total Current Liabilities from 2010 to 2024
PCRX Stock | USD 16.64 0.14 0.83% |
Total Current Liabilities | First Reported 2008-12-31 | Previous Quarter 92.7 M | Current Value 306.4 M | Quarterly Volatility 90.8 M |
Check Pacira BioSciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira BioSciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 79.4 M, Interest Expense of 15.8 M or Selling General Administrative of 63.1 M, as well as many indicators such as Price To Sales Ratio of 2.19, Dividend Yield of 0.0014 or PTB Ratio of 1.7. Pacira financial statements analysis is a perfect complement when working with Pacira BioSciences, Valuation or Volatility modules.
Pacira | Total Current Liabilities |
Latest Pacira BioSciences,'s Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Pacira BioSciences, over the last few years. Total Current Liabilities is an item on Pacira BioSciences, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pacira BioSciences, are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Pacira BioSciences,'s Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira BioSciences,'s overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
Timeline |
Pacira Total Current Liabilities Regression Statistics
Arithmetic Mean | 125,947,297 | |
Geometric Mean | 84,280,261 | |
Coefficient Of Variation | 100.39 | |
Mean Deviation | 77,889,269 | |
Median | 107,673,000 | |
Standard Deviation | 126,435,530 | |
Sample Variance | 15985.9T | |
Range | 507M | |
R-Value | 0.46 | |
Mean Square Error | 13513.7T | |
R-Squared | 0.22 | |
Significance | 0.08 | |
Slope | 13,110,069 | |
Total Sum of Squares | 223803.2T |
Pacira Total Current Liabilities History
About Pacira BioSciences, Financial Statements
Pacira BioSciences, investors use historical fundamental indicators, such as Pacira BioSciences,'s Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pacira BioSciences,. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Total Current Liabilities | 97.4 M | 123.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.